Pfizer Exec Urges National People’s Congress To Adopt Diversified Funding Mechanism For Biologics, Targeted Cancer Therapies
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer Inc.’s China Corporate Affairs Director Danglong Feng is the first executive from a multinational firm in China to serve as a delegate at the annual Chinese People’s Political Consultative Conference. Feng called on government, drug makers and insurers to create diversified funding mechanisms to widen access to innovative therapies in China.
You may also be interested in...
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.
China Biotechs, CDMOs Embrace Uncertain Future, New Options Amid WuXi Woes
The shockwave of WuXi's withdrawal from BIO is ripping through the Chinese contract services sector. While some remain hopeful, others are preparing Plan B.